CRISPR Therapeutics CRSP Operating Lease ROU Assets
Operating Lease ROU Assets at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.
The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about CRISPR Therapeutics's operating lease rou assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CRISPR Therapeutics's operating lease ROU assets?
- CRISPR Therapeutics (CRSP) reported operating lease ROU assets of $128.67M in Q1 2026.
- How has CRISPR Therapeutics's operating lease ROU assets changed year-over-year?
- CRISPR Therapeutics's operating lease ROU assets decreased by 8.3% year-over-year, from $140.28M to $128.67M.
- What is the long-term trend for CRISPR Therapeutics's operating lease ROU assets?
- Over 5 years (2020 to 2025), CRISPR Therapeutics's operating lease ROU assets has grown at a 21.0% compound annual growth rate (CAGR), from $50.87M to $131.72M.
- What does operating lease ROU assets mean?
- This asset represents the company's right to use a leased item, such as office space or data center facilities, over the lease term. It is recognized under modern accounting standards to reflect the financial commitment of long-term operating leases. It provides visibility into the company's fixed operational footprint.